UC Santa Barbara Students Get Bexsero to Treat Meningitis B - - BioPharm International

ADVERTISEMENT

UC Santa Barbara Students Get Bexsero to Treat Meningitis B



Novartis reported that its meningococcal serogroup B (MenB) vaccine, Bexsero (Meningococcal Group B Vaccine), will be used as part of a vaccination program at the University of California Santa Barbara (UCSB). In the last three months, FDA has approved the use of Bexsero twice in response to MenB outbreaks at US college campuses. More than 5,000 students were vaccinated at Princeton University and 20,000 students will be offered vaccination at UCSB.
 
Bexsero is the only licensed broad coverage vaccine approved in Europe, Canada, and Australia to help protect against invasive meningococcal disease caused by serogroup B. It was approved for use in the US under a treatment Investigational New Drug designation.
 
Source: Novartis

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
FDA Practices Discourage Biologic Market Competition, Says PCMA White Paper
November 19, 2014
Author Guidelines

Click here